Send us a text

In this episode of WTR Small-Cap x Healthcare Spotlight crossover episode, we are joined by Lisata Therapeutics' (NASDAQ: LSTA) CEO David Mazzo, PhD and Chief Medical Officer Kristen Buck, MD to talk about, Certepetide, the company's novel solid tumor targeting and penetration technology with tumor microenvironment modifying properties. We also dive into the recently reported positive preliminary results from Lisata's lead program (Ascend), a Phase 2b study investigating Certepetide for metastatic pancreatic ductal adenocarcinoma (the most common and aggressive form of pancreatic cancer), Lisata's partnerships, and upcoming milestones.

Send us a text

In this two-part WTR Symposium Series podcast, "NEXT-GEN VEHICLES: Investing in Small Drones and Unmanned Vehicles", management of Micropolis Holding Company (MCRP), Ondas Holdings Inc. (ONDS), SES AI Corp, (SES) and Unusual Machines, Inc. (UMAC) join the Water Tower Research team including Founding Partner and CEO, Shawn Severson and Managing Director - Technology, Dr. John Roy. Drones are everywhere and stocks are moving up. Hear what 4 CEOs in the drone industry are saying about investing, consolidation, and the need for standards.

Stay tuned next week for part-two with WTR's Peter Gastreich!

Send us a text

In our latest WTR Small-Cap Spotlight x Healthcare Crossover, Cybin CEO Doug Drysdale joins Water Tower Research’s Tim Gerdeman and Senior Analyst Robert Sassoon to discuss the company's non-traditional financing strategy as it continues to advance its development pipeline. Drysdale also probes into data that highlight advantages that distinguish Cybin's lead program CYB003 from other aspiring late-stage novel therapies in the depression treatment landscape

Cybin (NYSE: CYBN) is a late-stage clinical development company focused on developing novel psychedelic-based neuropsychiatric compounds. Its two lead candidates, targeting two of the most pervasive mental health disorders, are psilocin-based CYB003 for Major Depressive Disorder (MDD), currently being dosed in a Phase 3 program, and DMT-based CYB004 for General Anxiety Disorder (GAD) which is wrapping up a Phase 2 study.